Chemotherapy-Induced Nausea And Vomiting Therapeutics Market

Chemotherapy-Induced Nausea And Vomiting Therapeutics Market Size and Share Forecast Outlook 2025 to 2035

The Chemotherapy-Induced Nausea And Vomiting Therapeutics Market is estimated to be valued at USD 6.9 billion in 2025 and is projected to reach USD 13.0 billion by 2035, registering a compound annual growth rate (CAGR) of 6.5% over the forecast period.

Quick Stats for Chemotherapy-Induced Nausea And Vomiting Therapeutics Market

• Chemotherapy-Induced Nausea And Vomiting Therapeutics Market Value (2025): USD 6.9 billion
• Chemotherapy-Induced Nausea And Vomiting Therapeutics Market Forecast Value (2035): USD 13.0 billion
• Chemotherapy-Induced Nausea And Vomiting Therapeutics Market Forecast CAGR: 6.5%
• Leading Segment in Chemotherapy-Induced Nausea And Vomiting Therapeutics Market in 2025: Dopamine Antagonists (36.6%)
• Key Growth Regions in Chemotherapy-Induced Nausea And Vomiting Therapeutics Market: North America, Asia-Pacific, Europe
• Top Key Players in Chemotherapy-Induced Nausea And Vomiting Therapeutics Market: Kyowa Kirin, Inc., Pfizer Inc., GlaxoSmithKline plc., AbbVie Inc. (Allergan plc), Merck & Co., Inc., Bausch Health Companies Inc., Novartis AG, Ono Pharmaceutical Co., Ltd., Camurus AB, Heron Therapeutics, Inc.

Chemotherapy-Induced Nausea And Vomiting Therapeutics Market Key Takeaways

Metric	Value
Chemotherapy-Induced Nausea And Vomiting Therapeutics Market Estimated Value in (2025 E)	USD 6.9 billion
Chemotherapy-Induced Nausea And Vomiting Therapeutics Market Forecast Value in (2035 F)	USD 13.0 billion
Forecast CAGR (2025 to 2035)	6.5%

Why is the Chemotherapy-Induced Nausea And Vomiting Therapeutics Market Growing?

The Chemotherapy-Induced Nausea and Vomiting Therapeutics market is witnessing steady growth, driven by the increasing prevalence of cancer and the widespread use of chemotherapy as a standard treatment. Despite advances in oncology, nausea and vomiting remain among the most distressing side effects, creating high demand for effective therapeutic solutions. Continuous innovations in antiemetic drug development, particularly the use of targeted receptor antagonists and combination regimens, are improving patient quality of life and treatment adherence.

The rising burden of cancer cases worldwide, coupled with increasing healthcare access in developing regions, is contributing to the market’s expansion. Hospitals and specialty centers are adopting advanced therapeutics to reduce complications and improve treatment outcomes, further enhancing demand. Moreover, patient-centric approaches and supportive care strategies are pushing healthcare providers to integrate nausea and vomiting therapeutics into routine cancer management.

Growing investment in clinical research, regulatory approvals for newer agents, and wider distribution networks are also strengthening the market outlook As oncology treatment protocols evolve, effective control of chemotherapy-induced nausea and vomiting is expected to remain a vital aspect of comprehensive cancer care.

Segmental Analysis

The chemotherapy-induced nausea and vomiting therapeutics market is segmented by therapy type, distribution channel, route of administration, and geographic regions. By therapy type, chemotherapy-induced nausea and vomiting therapeutics market is divided into Dopamine Antagonists, Serotonin Receptor Antagonists, Corticosteroids, Benzodiazepines, and Neurokinin NK1 Receptor Antagonist.

In terms of distribution channel, chemotherapy-induced nausea and vomiting therapeutics market is classified into Hospital Pharmacy, Drug Stores, Retail Pharmacy, and E-Commerce. Based on route of administration, chemotherapy-induced nausea and vomiting therapeutics market is segmented into Oral and Intravenous.

Regionally, the chemotherapy-induced nausea and vomiting therapeutics industry is classified into North America, Latin America, Western Europe, Eastern Europe, Balkan & Baltic Countries, Russia & Belarus, Central Asia, East Asia, South Asia & Pacific, and the Middle East & Africa.

Insights into the Dopamine Antagonists Therapy Type Segment

The dopamine antagonists segment is projected to hold 36.6% of the market revenue in 2025, positioning it as the leading therapy type. Growth in this segment is being driven by the widespread availability, proven efficacy, and relatively low cost of dopamine antagonists compared to newer therapeutic agents. These drugs are frequently used in both prophylactic and rescue therapy for chemotherapy patients, reducing acute nausea and vomiting episodes effectively.

Their established role in clinical practice, supported by strong physician familiarity and patient accessibility, contributes to continued market leadership. Moreover, their broad availability across hospital and retail pharmacies ensures widespread adoption, particularly in emerging economies where cost constraints are significant.

Although newer classes of antiemetics are being introduced, dopamine antagonists remain a cornerstone in combination regimens due to their complementary mechanism of action The affordability and reliability of this therapy type ensure continued use, with ongoing research aimed at improving formulations and reducing side effects further strengthening the market outlook for dopamine antagonists.

Insights into the Hospital Pharmacy Distribution Channel Segment

The hospital pharmacy segment is expected to account for 35.6% of the market revenue in 2025, establishing itself as the leading distribution channel. Growth is being driven by the critical role hospitals play in administering chemotherapy and associated supportive treatments. Patients undergoing chemotherapy often rely on hospital pharmacies for immediate access to antiemetic drugs, ensuring timely intervention during treatment cycles.

Hospital pharmacies are preferred for their ability to dispense prescription-only medications, provide physician oversight, and manage drug safety protocols. The growing prevalence of cancer worldwide and the increasing number of hospital-based oncology centers are reinforcing this trend. In addition, hospital pharmacies serve as key distribution hubs for novel and specialized therapeutics that may not yet be widely available in retail settings.

Their integration with oncology care teams allows for effective patient monitoring, dosage adjustments, and coordinated treatment approaches As the complexity of cancer treatment increases, the reliance on hospital pharmacies for comprehensive care and access to advanced antiemetics is expected to sustain their dominant position in the market.

Insights into the Oral Route of Administration Segment

The oral route of administration is anticipated to hold 57.1% of the market revenue in 2025, making it the dominant method of delivery. This preference is primarily driven by patient convenience, ease of administration, and the ability to manage symptoms outside clinical settings. Oral formulations empower patients to maintain adherence to prescribed regimens without requiring hospital visits, thereby improving quality of life during chemotherapy cycles.

The availability of a wide range of oral antiemetics, including tablets and capsules, has further facilitated accessibility. Additionally, oral formulations often provide cost advantages compared to injectable therapies, broadening their appeal across both developed and developing markets. The increasing focus on outpatient care and home-based cancer management has further accelerated adoption of oral routes.

Pharmaceutical advancements in extended-release formulations and combination therapies are improving effectiveness and reducing dosing frequency, supporting patient compliance As healthcare systems continue to emphasize patient-centered care and cost-efficient models, the oral segment is expected to maintain its leadership, reinforced by growing demand for self-administered therapeutic solutions.

Chemotherapy-Induced Nausea And Vomiting Therapeutics Market Overview

Cancer is a leading cause of death worldwide, accounting nearly 1.4 million new cases in 2025. The most common cause of cancer is lung cancer accounting about 1.59 million deaths, globally. Other prominent cancers are liver cancer, breast cancer, stomach cancer, esophageal and stomach cancer.

In 2025, nearly 8.2 million deaths occurred from aforementioned indication, globally. Cancer can be treated by surgery, chemotherapy, radiation therapy, hormone therapy, targeted therapy, precision medicine and stem cell transplantation.

The most common treatment for cancer is chemotherapy; it uses drugs to kill cancer cells that cause pain and other problems. Chemotherapy may be used in combination with other cancer treatments. Chemotherapy given before surgery and radiation therapy to make the tumor cell smaller is known as neo-adjuvant chemotherapy and chemotherapy given after treatment with surgery or radiation therapy is known as adjuvant chemotherapy.

Chemotherapy, not only kills the cancer cells but also attacks healthy cells that leads to side effects such as fatigue, hair loss, nausea, and vomiting. Chemotherapy-Induced Nausea and Vomiting (CINV) is one of the most serious side effects that is taken into account.

Chemotherapy-induced nausea and vomiting are classified as acute, that occurs within 24 hours of the treatment; anticipatory, that is triggered due to some exposed stimuli; other are refractory; delayed and breakthrough. Incidence, timing, and intensity of chemotherapy-induced nausea and vomiting vary on chemotherapeutic agents and patient factors. CINV occurs in about 80% of patients and has a severe impact on patient’s life.

Antiemetics are less effective in controlling nausea and vomiting because the intensity is high than actual vomiting. Proper antiemetics can prevent CINV in about 60%-70% of patients. Nowadays due to research and development in the field of cancer therapeutics, many treatment options are available to manage and treat CINV by addressing antiemetic property to an individual patient.

Conventionally Chemotherapy-Induced Nausea and Vomiting was managed with dopamine receptor antagonists only. Currently, multiple options are available that is used in the prevention and management of CINV.

Analysis of Chemotherapy-Induced Nausea And Vomiting Therapeutics Market By Key Countries

Country	CAGR
China	8.8%
India	8.1%
Germany	7.5%
Brazil	6.8%
USA	6.2%
UK.	5.5%
Japan	4.9%

Country-wise Analysis

The Chemotherapy-Induced Nausea And Vomiting Therapeutics Market is expected to register a CAGR of 6.5% during the forecast period, exhibiting varied country level momentum. China leads with the highest CAGR of 8.8%, followed by India at 8.1%. Developed markets such as Germany, France, and the UK. continue to expand steadily, while the USA is likely to grow at consistent rates.

Japan posts the lowest CAGR at 4.9%, yet still underscores a broadly positive trajectory for the global Chemotherapy-Induced Nausea And Vomiting Therapeutics Market. In 2024, Germany held a dominant revenue in the Western Europe market and is expected to grow with a CAGR of 7.5%.

The USA Chemotherapy-Induced Nausea And Vomiting Therapeutics Market is estimated to be valued at USD 2.6 billion in 2025 and is anticipated to reach a valuation of USD 2.6 billion by 2035. Sales are projected to rise at a CAGR of 0.0% over the forecast period between 2025 and 2035. While Japan and South Korea markets are estimated to be valued at USD 351.8 million and USD 195.3 million respectively in 2025.

Key Players in the Chemotherapy-Induced Nausea And Vomiting Therapeutics Market

• Kyowa Kirin, Inc.
• Pfizer Inc.
• GlaxoSmithKline plc.
• AbbVie Inc. (Allergan plc)
• Merck & Co., Inc.
• Bausch Health Companies Inc.
• Novartis AG
• Ono Pharmaceutical Co., Ltd.
• Camurus AB
• Heron Therapeutics, Inc.

Scope of the Report

Item	Value
Quantitative Units	USD 6.9 Billion
Therapy Type	Dopamine Antagonists, Serotonin Receptor Antagonists, Corticosteroids, Benzodiazepines, and Neurokinin NK1 Receptor Antagonist
Distribution Channel	Hospital Pharmacy, Drug Stores, Retail Pharmacy, and E-Commerce
Route Of Administration	Oral and Intravenous
Regions Covered	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Covered	United States, Canada, Germany, France, United Kingdom, China, Japan, India, Brazil, South Africa
Key Companies Profiled	Kyowa Kirin, Inc., Pfizer Inc., GlaxoSmithKline plc., AbbVie Inc. (Allergan plc), Merck & Co., Inc., Bausch Health Companies Inc., Novartis AG, Ono Pharmaceutical Co., Ltd., Camurus AB, and Heron Therapeutics, Inc.

Chemotherapy-Induced Nausea And Vomiting Therapeutics Market by Segments

Therapy Type:

• Dopamine Antagonists
• Serotonin Receptor Antagonists
• Corticosteroids
• Benzodiazepines
• Neurokinin NK1 Receptor Antagonist

Distribution Channel:

• Hospital Pharmacy
• Drug Stores
• Retail Pharmacy
• E-Commerce

Route Of Administration:

• Oral
• Intravenous

Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa